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INTRODUCTION 
 
Diabetes is one of the most common chronic diseases affecting people world 
wide. The increasing prevalence of Diabetes all over the world is a major public 
health concern. The prevalence of diabetes in the adults will rise from 135 million 
in 1995 to 300 million by the year 2025, and more than 75% of the diabetics will 
reside in developing countries as compared to 62% in 1995. By 2025, India, 
China and the U.S will have the largest number of people with diabetics [1]. 
Several factors have contributed to the increasing burden of diabetes. These 
include a specific increase in risk factors for type 2 diabetes, such as increasing 
obesity [2, 3], lack of adequate physical activity [4], and life style and food changes 
induced by urbanization. Another factor contributing to apparent increase in the 
prevalence of diabetes has been the improvement in surveillance systems for 
diabetes, which has allowed better assessment of the true burden of diabetes [5]. 
Along with increased incidence of diabetes, complications caused by diabetes 
are also on the rise. Diabetes has its influence on multi-organ involvement in 
chronic diseases. Diabetes affects every organ due to macrovascular, 
microvascular and metabolic changes.  
Diabetic cystopathy (DC) is a chronic known complication among diabetics with 
prevalence of 26% to 87% [6]. It has a significant impact on day-to-day life, 
predisposes individuals to urinary tract infections (UTIs), potentiates renal 
complications and compromises optimum health. It is characterized by impaired 
bladder sensations, increased bladder capacity, decreased detrusor contractility 
and increased residual urine. Diabetic cystopathy develops insidiously and 
symptoms do not appear until the disease is well advanced. The classic 
symptoms of diabetic cystopathy which have been described have not always 
been observed in diabetic patients and these subjects often demonstrate variable 
symptom presentations. Initially the patient may be entirely asymptomatic, but 
demonstrate abnormalities on urodynamic study [7]. If bladder dysfunction is 
diagnosed earlier, corrective measures like strict glycemic control, changing the 
voiding pattern to timed voiding or double voiding may halt the deterioration of 
renal function, decrease the chance of urinary tract infection and halt progression 
of cystopathy further. Many authors have proposed that the diabetic cystopathy 
as a component of diabetic neuropathy which occurs in subjects with long 
standing diabetes. A weak association between glycemic control and neuropathic 
changes has been documented in both type 1 and type 2 diabetes. A possible 
link between deterioration of renal function and chronic asymptomatic bacteriuria 
in individuals with diabetes and bladder dysfunction also has been postulated [8, 
9]. Lack of association between cystopathy and progression of diabetic 
nephropathy was shown in another study [10]. In this scenario, it is imperative for 
the treating physicians to diagnose bladder dysfunction in diabetics at an 
asymptomatic stage and institute early treatment for this condition to prevent or 
delay complications like recurrent urinary tract infection, urolithiasis, urinary 
incontinence and renal failure.  
 
 
 
 AIM OF THE STUDY 
To estimate the prevalence and pattern of occult bladder 
dysfunction in diabetic subjects of 18 to 60 years age attending 
endocrinology outpatient clinic.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
NEURAL CONTROL OF LOWER URINARY TRACT 
The bladder performs two important functions. First, it stores the urine resulting 
from continuous excretory process of the kidneys into a more convenient, socially 
acceptable and adequate volume. Second, bladder empties the urine with 
synchronous activation of all the smooth muscle resulting in uniform pressure 
rise. The lower urinary tract receives innervations from three sources: 
sympathetic, parasympathetic and somatic nervous systems (Figure 1). The 
sympathetic system controls urine storage while the parasympathetic is 
responsible for bladder emptying. The somatic system which is under voluntary 
control is used in reinforcement of the external urethral sphincter and pelvic floor.  
Parasympathetic supply 
The pre-ganglionic parasympathetic fibres with cell bodies in the 
intermediolateral grey columns of the sacral segments of S2 to S4 run in the 
pelvic splanchnic nerves through the pelvic plexus. Autonomic ganglia are 
present not only within the nerve trunks and plexus, also on its more peripheral 
branches as they ramify on and within the bladder wall.  
Sympathetic supply 
Pre-ganglionic sympathetic fibres with cell bodies in the intermediolateral grey 
areas of the thoracic and lumbar segments T10 to L2 travel in the sympathetic 
chain and then via the lumbar splanchnic nerves to the superior hypogastric 
plexus. From there the right and left hypogastric nerves ramify with the pelvic 
plexus. Sympathetically mediated inhibition of the bladder depends not on  
NEUROANATOMY OF LOWER URINARY TRACT 
 
Figure 1. Innervation of lower urinary tract: Diagram showing the sympathetic, 
parasympathetic, and somatic innervation of the urogenital tract of male cat. Sympathetic 
preganglionic pathways emerge from the lumbar spinal cord and pass to the sympathetic chain 
ganglia (SCG) and then through the inferior splanchnic nerves (ISN) to the inferior mesenteric 
ganglia (IMG). Preganglionic and postganglionic sympathetic axons then travel in the hypogastric 
nerve (HGN) to the pelvic plexus and the urogenital organs. Parasympathetic preganglionic 
axons that originate in the sacral spinal cord pass in the pelvic nerve to ganglion cells in the 
pelvic plexus and to distal ganglia in the organs. Sacral somatic pathways are contained in the 
pudendal nerve, which provides an innervation to the penis, the ischiocavernosus (IC), 
bulbocavernosus (BC), and external urethral sphincter (EUS) muscles. The pudendal and pelvic 
nerves also receive postganglionic axons from the caudal sympathetic chain ganglia. These three 
sets of nerves contain afferent axons from the lumbosacral dorsal root ganglia. PG, prostate 
gland; U, ureter; VD, vas deferens. 
(Adapted from Wein: Campbell-Walsh Urology, 9th ed. Physiology and Pharmacology of the 
Bladder and Urethra, p1937)  
direct effects from noradrenergic fibres on the detrusor, but indirectly, by 
inhibition of the excitatory parasympathetic supply within the ganglia of the pelvic 
plexus. Noradrenaline released from the post-ganglionic sympathetic fibres, may 
be either excitatory or inhibitory depending on the predominant receptor type. 
Beta-receptors, producing relaxation have been shown to predominate in the 
vault of the bladder, while alpha-receptor sites producing contraction 
predominate in the bladder base.  
Somatic nerve supply 
The external urethral sphincter motoneurons are located along the lateral border 
of the ventral horn, commonly referred to as Onuf's nucleus [11]. Sphincter 
motoneurons also exhibit transverse dendritic projections into the lateral 
funiculus, intermediate gray matter and toward the central canal. Sacral somatic 
pathways are contained in the pudendal nerve, which provides an innervation to 
the external genitalia and perineal muscles. The pudendal and pelvic nerves also 
receive postganglionic axons from the caudal sympathetic chain ganglia. 
Afferent Pathways  
Visceral afferent fibres travel with both sacral and thoracolumbar visceral afferent 
nerves. Sacral afferents are evenly distributed between muscle and submucosa 
throughout the bladder; convey the sensations of touch, pain and bladder 
distension and are essential to complete normal micturition. Afferent axons in the 
pelvic, pudendal and hypogastric nerves transmit information from the lower 
urinary tract to the sacral and rostral lumbar dorsal root ganglia (DRG) which has 
their primary afferent neurons [12, 13]. The central axons of the DRG neurons carry 
the sensory information from the lower urinary tract to second-order neurons in 
the spinal cord and visceral afferent fibers travel rostrocaudally within 
posterolateral (Lissauer's) tract. [9, 14, 15]. Pelvic nerve afferents consist of finely 
myelinated (Aδ) and unmyelinated (C) axons. These fibers are silent afferent and 
becomes mechanosensitive and unmasks new afferent pathway during 
inflammation (Table 1). 
Table 1- Bladder afferent nerve fibers & their function 
Fiber Type Location Normal 
Function 
Inflammation Effect 
Aδ (finely 
myelinated 
axons) 
Smooth 
muscle 
Sense bladder 
fullness (wall 
tension) 
Increase discharge at lower 
pressure threshold 
C fiber 
(unmyelinated 
axons) 
Mucosa Respond to 
stretch (bladder 
volume sensors)
Increase discharge at lower 
threshold 
C fiber 
(unmyelinated 
axons) 
Mucosa 
muscle 
Nociception to 
overdistention 
Sensitive to irritants 
    Silent afferent Becomes mechanosensitive and 
unmasks new afferent pathway 
during inflammation 
 
Spinal and Supraspinal Pathways Involved in the Micturition Reflex  
Spinal Cord  
In the spinal cord, afferent pathways terminate on second-order interneurons that 
relay information to the brain or to other regions of the spinal cord including the 
preganglionic and motor nuclei. The axons of these second-order neurons cross 
the midline and ascend in the anterolateral quadrant of the contralateral half of 
the spinal cord, where they join the spinothalamic tract. The second-order 
neurons ultimately synapse on neurons in the ventral posterior lateral nucleus 
(VPL) of the thalamus. Interneuronal mechanisms must play an essential role in 
the regulation of lower urinary tract function [16]. Glutamic acid is the excitatory 
and γ-aminobutyric acid (GABA) and glycine are the inhibitory transmitters in 
these pathways [17]. Reflex pathways that control the external sphincter muscles 
also use glutamatergic excitatory and GABAergic and glycinergic inhibitory 
interneuronal mechanisms. The micturition reflex can be modulated at the level 
of the spinal cord by interneuronal mechanisms activated by afferent input from 
cutaneous and striated muscle targets. Stimulation of afferent fibers from various 
regions (anus, colon-rectum, vagina, uterine cervix, penis, perineum, pudendal 
nerve) can inhibit the firing of sacral interneurons evoked by bladder distention 
[18]. Suppression of detrusor overactivity in patients by sacral root stimulation may 
reflect in part activation of the afferent limb of these visceral-bladder and 
somatic-bladder inhibitory reflexes [19]. 
Pontine Micturition Center (PMC) 
Brainstem at the level of the inferior colliculus has an essential role in the control 
of the parasympathetic component of micturition [20]. The neurons in pontine 
micturition center (PMC) or the M region or Barrington nucleus send axon 
collaterals to the paraventricular thalamic nucleus (which is thought to be 
involved in the limbic system modulation of visceral behavior), periaqueductal 
gray region [21] (which regulates many visceral activities as well as pain 
pathways) and to multiple supraspinal neuronal populations that may coordinate 
micturition with other functions of the organism. Neurons in the PMC provide 
direct facilitatory inputs to bladder outflow [22] and inhibitory influence on external 
urethral sphincter motoneurons [21]. As a result of these reciprocal connections, 
the PMC can promote bladder-sphincter synergy.  
 
Central Pathways That Modulate the Micturition Reflex  
The influence of the cortex on voiding function could be mediated by pathways 
including direct cortical projections from the prefrontal cortex and insular cortex to 
the PMC or projections through the hypothalamus and the extra pyramidal 
system. Lesions to these areas of cortex appear to directly increase bladder 
activity by removing cortical inhibitory control.  
Applied anatomy 
The neuropathic process in diabetes involves large myelinated, small finely 
myelinated Aδ and unmyelinated C fibers in the peripheral and central nervous 
system causing an array of neurological involvement with mixed pattern.  It has 
been shown that spinal cord changes occurs in diabetes are similar to that of 
many demyelinating diseases like hereditary sensory motor neuropathy 
characterized by axonal atrophy and loss of anterior horn and dorsal root 
ganglion cells together with degeneration of the posterior columns in the spinal 
cord [23]. Bladder dysfunction is also considered as a manifestation of diabetic 
neuropathy.  Hyperglycemia is proposed to lead to microvascular and neurologic 
complications, the neurologic sequelae ultimately resulting in a loss of myelinated 
and unmyelinated fibers, wallerian degeneration, and blunted nerve fiber 
reproduction and function [24]. Involvement of afferent spinal and supraspinal 
tracts in diabetes may alter the pattern of inhibitory signals from central pathways 
to the sacral centers and predispose for detrusor overactivity as well as 
incontinence commonly seen in the clinical population with diabetic bladder 
dysfunction. 
 
PHYSIOLOGY OF MICTURITION  
Mechanisms governing the bladder to retain urine during the filling phase 
maintaining continence and expelling it when the desire void develops are a 
result of interplay between the autonomic and somatic nervous systems 
innervating bladder. The central pathways controlling lower urinary tract function 
are organized as simple on-off switching circuits that maintain a reciprocal 
relationship between the urinary bladder and the urethral outlet [25, 26]. Some 
reflexes promote urine storage, whereas others facilitate voiding. Individual 
reflexes are linked together in a serial manner to create complex feedback 
mechanisms. Alterations in these primitive reflex mechanisms may contribute to 
neurogenic bladder dysfunction. Direct activation of these reflexes by electrical 
stimulation of the sacral spinal roots very likely contributes to therapeutic effects 
of sacral nerve root neuromodulation [27].  
Filling and storage phase 
The bladder normally fills with urine at a rate of between 0.5 and 5 ml/minute and 
the bladder pressure rises only minimally. Even during the course of cystometry 
at rapid filling rates the pressure rises by no more than 15 cm H2O from empty to 
cystometric capacity. This ability to adapt to an increase in volume is called the 
compliance. During the early stages of bladder filling, proprioceptive afferent 
impulses from stretch receptors within the bladder wall pass via the pelvic nerves 
to sacral dorsal roots S2 to S4. These impulses ascend in the cord via the lateral 
spinothalamic tracts and descending impulses from the subcortical micturition 
centres subconsciously inhibit a detrusor motor response. As the bladder volume 
increases, the sensation of bladder filling associated with the desire to micturate 
is first consciously appreciated, usually at between 200 and 300 ml. The 
inhibition of detrusor contraction is now cortically mediated, although the desire 
to void may be further suppressed to subconscious levels again. With further 
filling, impulses within the visceral afferent fibres accompanying the sympathetic 
efferents to thoracolumbar roots T10 to L2 ascend to the cerebral cortex and a 
further desire to void is appreciated. During this time, in addition to the cortical 
suppression of detrusor activity, there may by a voluntary pelvic floor contraction 
in an attempt to maintain urethral closure. When a suitable time and site for 
micturition is selected the process of voiding commences. This may be 
considered in two phases, the initiation phase and the micturition phase. 
Initiation phase 
Relaxation of the pelvic floor [28] occurs early in the process. Simultaneous 
relaxation of the intrinsic striated muscle also occurs. Descending inhibitory 
influences from the cerebral cortex acting on the sacral micturition centre are 
suppressed, allowing a rapid discharge of efferent parasympathetic impulses via 
the pelvic nerves to cause detrusor contraction.  As the force of detrusor 
contraction increases, residual urethral resistance decreases further. Urine flow 
commences when the falling urethral pressure and increasing intravesical 
pressure equate.   
Micturition phase 
Since the bladder at the initiation of micturition takes on a nearly spherical shape 
and has walls which are thin in comparison to its radius, its behavior may be 
expressed by the law of Laplace (P. 2T/R), where P. pressure, T. tension, and R. 
radius. As the mural tension rises in the absence of voiding the intravesical 
pressure also rises. When a critical opening pressure is achieved, urine will start 
to flow and the bladder radius will fall. The pressure, however, usually remains 
constant during voiding and thus the mural tension must fall. While active tension 
is required throughout, the effectiveness of detrusor contraction increases as the 
muscle fibres shorten and therefore decreasing forces are required as micturition 
proceeds. If micturition is voluntarily interrupted midstream, contraction of the 
pelvic floor (pubococcygeus) causes the urethral pressure to rise rapidly to 
exceed the intravesical pressure and therefore urine flow stops. The detrusor, 
being a smooth muscle, is much slower to relax and therefore goes on 
contracting against the closed sphincter. Thus an isometric contraction occurs 
and again, applying the law of Laplace, the intravesical pressure rises. If 
micturition is resumed by relaxation of the pelvic floor, both urethral and 
intravesical pressures will return to their previous voiding state.  
 
Applied physiology  
In diabetic cystopathy, due to neuronal damage afferent input resulting from the 
stretch of bladder muscle as well as the mucosa is affected. As bladder filling 
occur progressively, affected individual tend to accumulate large volume of urine. 
Frequency of micturition is often reduced during the later stages of the disease to 
the extent of voiding once or twice in a day. Bladder detrusor, like cardiac and 
skeletal muscle follow the principle to stretch as stated in starling’s law of the 
heart [29]. As the detrusor stretches beyond the point where it can regain its 
tension, decompensation occurs. Detrusor can no longer expel urine in a single 
voiding. According to the law of Laplace, as the radius of distended bladder 
increases, mural tension decreases resulting in detrusor hypocontractility or 
acontractility.  Studies also indicate that reduced production of nerve growth 
factor (NGF) in the bladder and/or impaired transport of NGF to L6–S1 DRG may 
be an important mechanism inducing DM cystopathy, which is attributable to 
defects in both Aδ fiber and C-fiber bladder afferent pathways [30].  NGF gene 
therapy using replication-defective HSV vectors which restore decreased NGF 
expression in the bladder afferent pathways could be effective for treating DM 
cystopathy [31]. 
 
 
 
 
 
EFFECTS OF DIABETES ON THE LOWER URINARY TRACT  
Diabetes produces a spectrum of lower urinary tract manifestations with various 
symptoms. The bladder lesion due to diabetic neuropathy was first pointed out by 
Marchal de Calvi in 1864 [32]. Frimodt moller C coined the term “diabetic 
cystopathy” for the bladder symptoms occurring due to diabetes [6].  The classic 
triad of bladder symptoms associated with diabetic cystopathy includes 
decreased bladder sensation, increased bladder capacity, and impaired detrusor 
contractility with resultant increased postvoid residual (PVR) urine. Increased 
PVR leaves the individual prone to UTIs.   
However, many diabetic patients have concomitant lesions, such as benign 
prostatic hyperplasia, stress incontinence, bladder or prostate cancer and 
infection, which may coexist with or mimic the symptoms of diabetic cystopathy. 
As a result, these patients complain of a variety of lower urinary tract symptoms 
that may obscure the underlying etiology. In addition, diabetes is a systemic 
disease whose prevalence as well as spectrum of symptomatic severity varies 
greatly depending on the population examined [33, 34]. Consequently, the classical 
symptoms of diabetic cystopathy (DC), while well described, have not always 
been observed in the diabetic patient and these patients often demonstrate 
varied symptom presentations. In a retrospective study of 182 diabetic patients 
who underwent videourodynamic evaluation [35], 55% had detrusor hyperreflexia, 
23% had impaired detrusor contractility, 11% had indeterminate findings, 10% 
had detrusor areflexia and 1% was normal. Bladder outlet obstruction occurred in 
66 patients (36%). The diagnosis was isolated in 24 patients (36%) or in 
combination with another diagnosis in 42 (74%).This study indicated that 
classical diabetic cystopathy is not the most common urodynamic findings in 
patients with diabetes mellitus and voiding dysfunction, and in fact these patients 
present with variable pathophysiological findings.  
An important question is whether bladder dysfunction is secondary to an inherent 
neuropathology induced by diabetes, or caused by changes associated with 
bladder over distension. Many animal models have been used to elucidate this 
and other questions seen in diabetic patients associated with diabetic cystopathy. 
Streptozotocin (STZ) induced diabetic rats and sucrose drinking rats have 
generally been used. Paro et al noted that alloxan induced diabetic rats had 
decreased and irregular contractions, while sucrose fed rats had normal bladder 
contractions [36]. This suggested that in alloxan induced diabetes; contractile 
dysfunction is secondary to an inherent diabetic cystopathy, while bladder 
hypertrophy in sucrose fed rats is an organ adaptation to polyuria. Neuropathy in 
diabetics has been extensively studied in recent years [37, 38] but none of these 
large trials included outcome measures relating to bladder dysfunction. 
Increasingly, DC is described as a manifestation of autonomic neuropathy [39, 40]. 
Although some believe it also represents peripheral somatic neuropathy [41]. 
Several classification systems for diabetic neuropathy have been suggested, but 
none has included specific lower urinary tract function. Greene et al [42] proposed 
that genitourinary neuropathy fits within the autonomic neuropathy category, 
along with sudomotor, cardiovascular, and gastrointestinal neuropathy as 
classified by Thomas et al [43] (Table 2).  
Table 2 - Classification of diabetic neuropathy [43] 
 
Diffuse  
Distal symmetric sensorimotor polyneuropathy 
Autonomic neuropathy:  
           Sudomotor 
           Cardiovascular 
           Gastrointestinal  
           Genitourinary 
Symmetric proximal lower limb neuropathy (amyotrophy) 
Focal  
Cranial neuropathy 
Radiculopathy / plexopathy 
Entrapment neuropathy 
Asymmetric proximal lower limb neuropathy (amyotrophy) 
 
 
 
 
 
 
 
 
PATHOPHYSIOLOGY OF BLADDER DYSFUNCTION IN DIABETES 
The biology of diabetes associated bladder complications is multifactorial and 
they can be a result of an alteration in the physiology of the detrusor smooth 
muscle cell, the innervation or function of the neuronal component, or urothelial 
dysfunction.  
Diabetes and detrusor smooth muscle function: 
DM has been shown to alter detrusor smooth muscle function in experimental 
STZ rat model. Pharmacological studies on isolated bladder muscle strips have 
shown varied responses. They are increase in responsiveness of detrusor 
muscle to externally applied muscarinic agonists [44, 45], increase in muscarinic 
receptor density [46], and an increase in the beta 1- receptor-mediated relaxation 
of isolated detrusor smooth muscle strips [47].  Other changes are increased 
responsiveness of isolated rat bladder strips to electrical field stimulation (EFS) 
[48, 49], increased neurotransmitter release, increased calcium-channel activity [50] 
and changes in nitric oxide synthase (NOS) and reactive nitrogen species 
formation [51].  
Urothelial dysfunction in Diabetes:  
Urothelium regulates permeability, transport and endocytosis. Urothelium is not 
only a passive barrier against urea and ion diffusion, but that it can also function 
as a sensor, controlling bladder function and dysfunction. The urothelium have 
receptors and ion channels similar to those in bladder nerves, and injury or 
inflammation may alter the response of both urothelial cells and sensory afferents 
to nociceptive and other stimuli. Many mediators, e.g. ATP, NO and prostanoids, 
can be released from the urothelial cells [52, 53]. Vanilloid receptors are expressed 
on urothelial cells [54], and it has been shown that ATP can potentiate the 
response to vanilloids by lowering the threshold for, e.g. protons and capsaicin 
[55]. This means that the large amounts of ATP released from damaged/sensitized 
cells in response to injury/inflammation may influence afferent nerves and 
contribute to the variety of abnormalities in diabetes induced bladder dysfunction. 
In isolated urothelial layer preparations from bladders of STZ-Diabetic rats, the 
absolute amount of endogenous prostaglandins E2 and F2a was higher than in 
corresponding preparations from control animals [56]. ATP and bradykinin 
significantly increased the endogenous release of both prostaglandins from the 
urothelium. ATP and bradykinin receptors might be present in the urothelium and 
that these receptors may be important in, e.g. prostaglandin generation and 
release [57]. In turn, prostaglandins may sensitize sensory nerves and increase 
the sensitivity of bladder smooth muscle to contractile stimuli, which may 
contribute to some of the bladder abnormalities, e.g. detrusor overactivity, 
observed in diabetes. 
Diabetic neuropathy causing bladder dysfunction:  
The pathogenesis of diabetic neuropathy is multifactorial. Accumulating evidence 
suggests that the various pathogenic factors are interrelated and together 
contribute to the development and progression of the neuropathy [58, 59]. The 
actual process of neuropathic progression is dynamic (Figure 2), with nerve 
degeneration and regeneration occurring spontaneously and simultaneously. The 
net balance between these two processes determines whether the neuropathy 
progresses, regresses or stabilizes.  
Metabolic factors:  
The results from the Diabetes Control and Complications Trial (DCCT) 
convincingly demonstrated that hyperglycemia and insulin deficiency contribute 
significantly to the development of diabetic neuropathy [37, 60]. Most of our 
understanding of pathogenetic mechanisms in diabetic neuropathy comes from 
studies in diabetic rats. One of the most often cited mechanism account for the 
effects of hyperglycemia on diabetic neuropathy is the changes in the polyol 
pathway. This leads to cell’s inability to detoxify reactive oxygen species. 
Hyperglycemia also promotes formation of reactive oxygen species by auto-
oxidation of glucose and formation of advanced glycation end products. In 
diabetic animals, accumulation of sorbitol in nerves in the presence of 
hyperglycemia produces a reciprocal decrease in levels of myo-inositol and 
taurine which are effective osmolytes [61]. Myo-inositol and taurine depletion is 
associated with reduced Na+/K+ adenosine triphosphatase activity resulting in 
Na+ retention, edema, myelin swelling, axoglial disjunction, nerve degeneration 
and slowed nerve conduction velocity in the diabetic rat [61, 62, 63].  Aldose 
reductase inhibitors restore myoinositol and taurine levels and improve motor 
conduction velocity in diabetic rats [57, 64]. They also improve nerve conduction 
velocities and protect small sensory fibers from degeneration in humans.  In 
experimental diabetic neuropathy, antioxidant therapy has ameliorated signs of 
diabetic neuropathy [65].  
Microvascular insufficiency:  
Studies suggest that absolute or relative ischemia exists in the nerves of diabetic 
persons due to altered function of the endoneurial and/or epineurial blood 
vessels. Sural nerve biopsies from diabetic patients reveal many changes 
suggestive of endoneurial and epineurial microvasculopathy, including basement 
membrane thickening, endothelial cell proliferation, and vessel occlusions [66, 67].  
Ischemia secondary to vascular disease induces oxidative stress in the nerve, 
increasing the production of reactive oxygen species and inducing nerve injury. 
Hyperglycemia- induced depletion of nicotinamide-adenine dinucleotide 
phosphate [NADPH] stores, with subsequent loss of detoxification mechanisms, 
further exacerbates the damage resulting from ischemic oxidative stress.  
Growth factor deficiency:  
Neurotrophic factors are involved in the development, maintenance, and 
regeneration of responsive elements of the nervous system. The best studied of 
these is nerve growth factor (NGF), a protein that promotes the survival of 
sympathetic and small-fiber neural crest-derived sensory neurons in the 
peripheral nervous system. These neurons are frequently affected in diabetic 
polyneuropathy. In diabetic animal models, both NGF production and retrograde 
transport appear to be impaired [68]. In a human study, abnormal expression of 
NGF in skin keratinocytes correlates with early manifestations of small fiber 
sensory neuropathy. Nerve growth factor treatment of streptozocin-diabetic rats 
and diabetic patients in clinical trials appears to ameliorate manifestations of 
small-fiber sensory neuropathy [69]. Neurotrophic factors appear to play a 
significant role in mediating the cell’s defense against oxidative stress.  
Deficiency in the availability of these factors could further exacerbate the injury 
caused by oxidative stress. Antioxidant treatment also enhances NGF action [70]. 
The insulin-like growth factors (IGFs), IGF-I and IGFII, have been implicated in 
the growth and differentiation of neurons and IGF receptors are present in nerve 
tissues (e.g., neurons, Schwann cells, ganglia) involved in diabetes- associated 
nerve disorders. IGFs and their binding proteins (IGF-BPs) are regulated by 
insulin and the glycemic state [71, 72]. A consequence of insulin insufficiency is a 
reduced circulating IGF-I concentration.  
Immune mechanisms:  
Immune mechanisms may be responsible for the clinical neuropathic syndrome, 
especially in those with proximal neuropathy and those with a more marked 
motor component to their neuropathy. Circulating antineuronal antibodies are 
present in diabetic serum in some patients. The circulating autoantibodies 
directed against motor and sensory nerve structures have been detected by 
indirect immunofluorescence, and antibody and complement deposits in various 
components of sural nerves have been shown. Anti-Gangliomucopolysaccharide 
(Anti-GM1) antibodies and Antiphospholipid antibodies (anti-PLAs) have been 
demonstrated in diabetic patients with neuropathy, especially distal symmetrical 
polyneuropathy (DSPN) [72, 73]. PLAs are associated with a tendency to vascular 
thrombosis; their presence may provide a link between the immune and vascular 
theories of causation of neuropathy.  
 
Miscellaneous:  
Other possible contributors to diabetic nerve damage include decreased 
expression of laminin, a glycoprotein important in nerve regeneration and 
Deficiency of dihomo-g-linolenic acid (GLA) as well as N-acetyl-L-carnitine. [71].  
These mechanisms (Figure 2) appear to be working in unison to cause peripheral 
nerve degeneration in diabetic patients. Understanding these mechanisms 
provides opportunities for intervention. For example, aldose reductase inhibitors 
may offset the intracellular metabolic consequences of hyperglycemia, while 
antioxidants directly limit damage from reactive oxygen species. Neurotrophic 
factors, such as nerve growth factor, may also increase the resistance of the cell 
to injury from oxidative stress and at the same time promote regeneration of 
damaged nerves. All of these approaches are being investigated. Combination 
therapy may offer the greatest hope of ameliorating diabetic neuropathy (Figure 
2). Tight control of blood glucose decreases long-term neurologic and 
microvascular complications of diabetes, but the precise relationship of glycemic 
control and duration of diabetes to diabetic cystopathy (DC) is not known. It even 
has been suggested that blood glucose concentration affects the rate at which 
aging occurs and that diabetes may be a syndrome of premature aging. [74].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Steps in the proposed pathways that lead to the pathogenesis of 
diabetic neuropathy and possible interventions at the level of each proposed 
mechanism. [75] 
AII = angiotensin II; ACE = angiotensin-converting enzyme; AGE = advanced glycation end 
products; EFA = essential fatty acid (deficiency); ET = endothelin; GLA/EPO = g-linolenic 
acid/evening primrose oil; IGF = insulin-like growth factor; NGF=nerve growth factor; 
Nitrodil=nitrodilators; NO=nitric oxide; NT3=neurotrophin-3; PDIE= phosphodiesterase; PGI2 = 
prostacyclin.   
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PREVALENCE OF BLADDER DYSFUNCTION IN DIABETES 
Diabetic cystopathy develops insidiously and symptoms do not appear until the 
disease is well advanced [76]. The impact of disease duration and the method of 
treatment of diabetes on the development of diabetic cystopathy are not well 
established [35]. A large capacity bladder with concomitant retention and difficulty 
in voiding can occur in other diseases of non-diabetic origin [6]. Existing studies 
on diabetic cystopathy are generally characterized by a small number of cases 
that are selective either by studying subjects with diabetes of variable disease 
duration with urinary symptoms being referred for urologic examination or 
selecting a subgroup of patients with insulin dependent diabetes [76]. The 
prevalence of diabetic cystopathy in literature has been reported with different 
figures in various studies due to different definitions for cystopathy in them. Some 
investigators disregard the residual urine completely [6] and others accept over 90 
to 1000ml of residual urine as diagnostic of cystopathy [7, 77, 78, 79]. Some others 
define cystopathy when residual urine volume exceeds 500ml to 1200ml [7] or 
when over 50% of bladder capacity has been reached [9, 80].  
Frimodt-moller in urodynamic study of 124 diabetics (mainly insulin dependent 
diabetics), showed a prevalence of 38% of diabetic cystopathy [6]. Ellenberg & 
Weber [7] noted features of neurovesical involvement in 83% among 36 diabetic 
subjects with diabetic neuropathy when they compared the urodynamic and 
cystographic features of these subjects with normal 26 non-diabetic controls and 
24 diabetic patients without neuropathy. They proposed the existence of 
preparalytic bladder with features of neurovesical involvement before the onset of 
overt bladder dysfunction. Bartley et al had a prevalence of bladder dysfunction 
in 43% among 75 patients (28 men between 17 to 45 years old and 47 women of 
17 -73 years old) with diabetes hospitalized for various reasons with combined 
urodynamic and cytographic studies [79].  Faerman et al noted a prevalence of 
87% among 31 juvenile diabetics with average disease duration of 9 years using 
urodynamic and radiological techniques. Among those who had diabetes more 
than 10 years, 91% had bladder disturbances [9]. 
Fagerberg compared the cystometric, micturition urethrocystographic and pelvic 
floor electromyographic of 30 male hospitalized diabetics between 20 and 50 
years of age with age matched control of 25 healthy male blood donors. The 
prevalence in this study was 34% to 65% [78]. In unselected diabetic patients on 
insulin, the frequency of cystopathy was 43-44% [80]. Urodynamic abnormalities 
suggestive of bladder dysfunction was noted in 80% among 60 diabetics (35 
males and 25 females) by Buck et al. Electrophysiological testing in these 
patients revealed evidence of sensory defect in all of them [81]. The difference in 
the prevalence rates among all these studies may be due to1) lack of uniformity 
of definition of diabetic cystopathy 2) tools to diagnose bladder dysfunction and 
3) patients factors like variable disease duration, glycemic control and associated 
complications such as sensory and motor neuropathy.  
Kebapci et al evaluated 54 (27 men and 27 women) type 2 diabetic patients with 
LUTS  using urodynamic studies and analyzed various parameters like disease 
duration, presence of diabetic autonomic neuropathy, nephropathy and 
retinopathy. 74% of the men and 59% of women had abnormal urodynamically 
detected bladder dysfunction. 50% and 43.7% of men and women had features 
of diabetic cystopathy [82].  
 Various other Urodynamic abnormalities like bladder outflow obstruction and 
detrusor overactivity were also seen in significant number of patients. The 
diagnosis of diabetic cystopathy was established according to the following 
criteria: 1) Increased maximal bladder capacity 2) Impaired bladder sensation 
(volume at first desire to void >150ml) 3) decreased bladder contractility (a flat 
trace in cystometry) 4) post void residue of ≥ 100ml. Men with type 2 diabetes 
longer than 9 years and women with disease more than 8 – 9 years had higher 
risk of bladder dysfunction [82].  
Ishigooka et al evaluated 42 patients with diabetes who were referred to 
urodynamic evaluation. A prevalence of 50% of diabetic cystopathy was seen. 
Urodynamic evaluations consist of water cystometry, uroflowmetry and 
measurement of post void residual urine. Diabetic cystopathy was diagnosed 
when patients had 1) impaired detrusor contraction (poorly sustained, no or weak 
detrusor contraction, (less than 30cmH2O or by uroflowmetry maximum flow rate 
less than 10ml/sec with or without staining voiding pattern) 2) Sensory 
impairment as defined as increased capacity at first desire to void (over ½ of 
maximum cystometric capacity) and / or maximum cystometric capacity over 
600ml [83].  
Many authors have demonstrated variable prevalence rate of bladder dysfunction 
among diabetics in various series using different methods of assessment. 
Majority of these studies were done in patients being referred for urologic 
evaluation of their lower urinary tract symptoms or for other causes of 
hospitalization. There is paucity of studies describing the prevalence of bladder 
dysfunction among asymptomatic diabetic subjects who hasn’t been evaluated 
for any urological symptoms. Upto our knowledge, there is no study in India 
which addresses this entity of bladder dysfunction in asymptomatic patients. The 
main purpose of this study is to know the prevalence of occult bladder 
dysfunction among diabetic patients.  
 
ASSESSMENT OF BLADDER DYSFUNCTION IN DIABETES 
As bladder dysfunction develops insidiously and often is detected when the 
clinical stage of the disease reaches an advanced stage, it was thought that 
urodynamic studies are mandatory for diagnosis of these conditions at the earlier 
stage [79]. In earlier series, bladder dysfunction was diagnosed when patients 
were referred for urodynamic evaluation in view of their lower urinary tract 
symptoms. Few studies have attempted to do estimate the prevalence of bladder 
dysfunction using non-invasive techniques like uroflowmetry and American 
urological Association (AUA) symptom index [84]. Uroflowmetry and post void 
residual urine of 182 diabetic female patients were compared with 197 normal 
healthy women [84]. Women with high AUA score index and lower maximum 
uroflow are noted to be likely parameters for bladder dysfunction. 25.8% of the 
women with type 2 diabetes in this study had bladder dysfunction. Lower 
maximum flow rate (<15ml/sec), Post void residual urine more than 100ml and 
Bladder voiding efficiency (BVE) {calculated as BVE = 100% X volume voided / 
(volume voided + PVR)} less than 75% are defined as suggestive of bladder 
dysfunction in this study. In another study, an early disturbance of detrusor 
contraction noted by retarded uroflow in diabetic children and adolescents was 
interpreted as early sign of autonomic neuropathy. It has been suggested to use 
uroflowmetry to determine the autonomic neuropathy in them [85]. 
 Estaghamati et al suggested the search for microvascular complications like 
neuropathy, retinopathy and nephropathy might be used to screen for 
components of diabetic cystopathy in its asymptomatic phase. 66 (26 males and 
40 females) with low AUA symptom score were evaluated urodynamically along 
with assessment of microvascular complications. 29.2% of men had bladder 
outflow obstruction, 75% of women and 48% of men had increased bladder 
capacity, and 16.7% of patients had decreased compliance. Presence of somatic 
neuropathy on extremities suggested the low flow rate in the urodynamic study. 
Diabetic retinopathy had negative correlation with detrusor instability in this 
study. This study suggested the screening for diabetic cystopathy before the 
symptoms appear [86].  
Prospectively voiding function of 176 diabetic women and 162 age matched 
nondiabetic women was assessed by AUA index questionnaire, uroflowmetry 
and post void residual urine estimation by urethral catheterization was done by 
Yu et al [87].  Maximum flow rate less than 12ml/sec at a minimum voided volume 
of atleast 150ml and post void residue more than 100ml was diagnostic of 
unrecognized voiding difficulty. Unrecognized voiding difficulty in diabetic women 
was 4.8 times more than in normal women. It was suggested that uroflowmetry 
and AUA symptoms score might be used to identify those diabetic patients who 
are at risk of developing bladder dysfunction [87]. 
Although uroflowmetry and AUA symptom index are not specific to identify 
detrusor impairment, both these non-invasive parameters were suggested as 
tools to decide on the indication for further urodynamic investigations in diabetic 
patients [83, 84, 85] .  In this study we used uroflowmetry and AUA symptom score to 
decide upon the further need for urodynamic in our study patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PATIENTS AND METHODS 
Research Question: 
1. What is the prevalence of occult bladder dysfunction among diabetic subjects 
between 18 to 60 years of age from Tamilnadu attending endocrinology-
diabetic outpatient clinic?  
2. What is the pattern of bladder dysfunction among the studied subjects? 
3. Is there any association between the prevalence of bladder dysfunction 
between symptomatic and asymptomatic subjects? 
4. Is there an association between bladder dysfunction and microvascular 
complications of diabetes? 
Inclusion Criteria:  
1. All Tamil speaking diabetic subjects between 18 to 60 years of age attending 
endocrinology – diabetic outpatient clinic. 
Exclusion Criteria:  
1. Previous surgery of urethra, prostate or bladder. 
2. Previous pelvic procedures likely to cause bladder denervation like 
Hysterectomy and Abdominoperineal excision of rectum. 
3. Neurological diseases likely to influence the lower urinary tract except 
autonomic neuropathy.  
4. Overactive bladder, Bladder outlet obstruction or any other abnormal 
urodynamic findings.  
5. Bladder calculus. 
6. Bacterial and tuberculous cystitis  
7. Medications like anticholinergics, diuretics, antidepressants and 
antipsychotics. 
Calculation of sample size: 
The sample size was calculated from a retrospective study analyzing the 
prevalence of bladder dysfunction among symptomatic diabetic patients who 
were referred and urodynamically evaluated in the department of urology for a 
period of three years. The prevalence of diabetic cystopathy was 40%. The 
sample size required to find a prevalence of 40% with a precision of ± 10% and 
with a 95% confidence was 100. Sample size was calculated using the formula: 
4pq / d², where p is 40%, q = 1-p = 60%, d = 10%. The primary endpoint was to 
estimate the prevalence of occult bladder dysfunction.  
Methodology:  
The study was conducted in the endocrinology- diabetic outpatient clinic and 
urology department of Christian medical college, Vellore.  This was prospective 
cohort study. Diabetic subjects of age group of 18 to 60 years attending the 
endocrinology outpatient clinic were recruited for the study. Those who fulfill the 
inclusion and exclusion criteria were subjected for the study after written 
informed consent. They were asked to answer an international prostatic symptom 
score (IPSS) questionnaire (annexure 1). All subjects did a representative 
uroflowmetry. Post void residual urine was measured using abdominal ultrasound 
using prolate ellipsoid formula; Volume (V) in ml = Length x Height x transverse 
diameter x π/6 or 0.53.  All maintained a bladder diary for 24 hours in their 
homes and returned the form during next visit. Those who have moderate lower 
urinary tract symptoms (LUTS) as indicated by (IPSS score ≥ 8) or have a peak 
flow of less than 15ml/sec at a voided volume more than 150ml were subjected 
for urodynamic evaluation. All the demographic and clinical data were recorded 
in the proforma (annexure 2). Evaluation of patients began with detailed history 
of duration of diabetes, duration of LUTS, nature of LUTS, presence of 
incontinence / hematuria / calculuria/ necroturia / urinary tract infection / voiding 
dysfunction/ instrumentation, symptoms of cardiac/ peripheral vascular / 
neurological diseases. Physical examination details as recorded by diabetologist 
(co-investigator) were also entered. Urological clinical assessment was done by 
the investigator. Evaluation for concomitant diabetic neuropathy, nephropathy 
and retinopathy was carried out in all patients. Estimation of serum creatinine, 
Fasting and 2-hours post prandial glucose, HbA1C, Fasting lipid profile, 
Microalbumin or 24-hour urinary proteins and urine microscopy was done for all. 
Urine culture and sensitivity was done for those who were subjected to 
urodynamics. Ultrasonogram of the abdomen and X-ray of the KUB region was 
done for those who had other abdominal symptoms, microhematuria and renal 
failure. Those who have asymptomatic bacteriuria were included in the study. 
Those who have positive culture with LUTS were excluded from the study. The 
pressure-flow studies were done using medical measurement systems (MMS) 
UD 2000 equipment. Gentamicin Sulphate 160mg and Cefotaxime 1g was given 
intravenously as prophylactic antibiotics for those who had normal renal function 
and those with renal failure respectively. No antibiotic prophylaxis was given after 
urodynamic study. Pretest residue was measured prior to urodynamic evaluation 
by placing two 6Fr infant feeding tubes. One of these tubes was used for filling as 
well as for intravesical pressure measurement.  During cystometry in sitting 
posture, bladder was filled with physiological saline at 37ºC at a filling rate of 
50ml/min. First sensation of bladder filling (ml), maximum cystometric capacity 
(ml), detrusor overactivity (presence or absence), incontinence (presence or 
absence), and compliance (cmH2O) were assessed during filling phase. 
Maximum urinary flow (Qmax, ml/sec), Maximum intravesical pressure on voiding 
(cmH2O), Voided volume (ml), events like abdominal straining were noted during 
voiding phase. Abdominal pressure was recorded by using perforated rectal 
balloon catheter. Detrusor pressure was calculated by subtracting intra-
abdominal pressure from intravesical pressure.  Detrusor pressure at maximum 
urinary flow rate (Pdet at Qmax, cm H2O) was measured to evaluate detrusor 
contractility. Methods, definitions and units were appropriate to the standards 
recommended by the international continence society. In those who did not 
undergo urodynamics, uroflowmetry, estimation of residual urine, bladder voiding 
efficiency (BVE) were the parameters evaluated to study bladder dysfunction. 
BVE was calculated by BVE= 100% x volume voided / (volume voided+ post void 
residue). BVE less than 75% was chosen as the cutoff point of bladder 
dysfunction.  
 
 
 
 
Definition:  
1) Urinary incontinence was defined if the complaint of any involuntary 
leakage of urine was present in which stress urinary incontinence (the 
complaint of involuntary leakage on effort on exertion, or on sneezing or 
coughing), or urge urinary incontinence (the complaint of involuntary leakage 
accompanied by or immediately preceded by urgency) were noted. 
2) Normosensitive bladder - Volume at first sensation of 150 -200ml 
3) Delayed first sensation – Appreciation of first sensation of filling at volume 
≥250ml or greater than 50% of maximal cystometric capacity.  
4) Detrusor overactivity – Involuntary phasic increase in detrusor pressure 
that was difficult to control or could not be controlled by patient resulting in 
incontinence or voiding.  
5) Normal compliance – Filling detrusor pressure of 5-20cmH2O in the 
absence of simultaneous detrusor contraction at maximum cystometric 
capacity.    
6) Normal maximum cystometric capacity – Volume 350 to 600ml, at which 
there was bladder contraction that resulted in voiding or patient discomfort. 
7) Normal urinary flow rate – Catheterized urine flow rate of more than 
12ml/sec.  
8) Normal Pdet at Qmax - > 10cm H2O or <40cmH2O during voiding with 
catheterized flow rate if more than 12ml/sec. 
9) Normal post void residue – 50ml  
10) Hypocontractile detrusor – Pdet at Qmax less than 10cmH2O or flat trace 
during voiding with or without abdominal straining.  
11) Bladder outflow obstruction – Pdet at Qmax more than 40cmH2O with 
catheterized urine flow rate less than 12ml/sec.  
12) Bladder dysfunction (among those who had urodynamics): Presence of 
2 or more of the following findings 
a. First sensation of filling at volume more than 250ml or 50% of maximum 
cystometric capacity 
b. Maximum cystometric capacity more than 600ml 
c. Compliance >20cmH2O 
d. Detrusor overactivity 
e. Pdet at Qmax <10 / >40cmH2O with catheterized flow rate less than 
12ml/sec 
f. Post void residue more than 50ml. 
13) Bladder dysfunction (among those who did not have urodynamics): 
Presence of 2 or more of the following findings 
a. Voided volume more than 600ml or less than 150ml 
b. Post void residue more than 50ml 
c. Bladder voiding efficiency less than 75% 
14) Diabetic nephropathy 
a. Microalbuminuria: ≥30mg/day  
b. Macroalbuminuria: >300mg/day  
 
15) Diabetic retinopathy  
a. Presence of background, nonproliferative or proliferative retinopathy 
b. History of laser retinal photocoagulation / vitreoretinal surgery in the 
course of diabetes 
16) Diabetic neuropathy: Presence of more than 2 of the following elements 
a. Biothesiometry >20mv 
b. Monofilament >4g 
c. Deep tendon reflexes - absent or decreased 
d. Trophic ulcers 
17) Overt Diabetic cystopathy: Presence of 3 or more of the following elements  
a. First sensation of bladder filling at >250ml or 50% of maximum cystometric 
capacity 
b. Maximum cystometric capacity >600ml 
c. Pdet at Qmax <10cmH2O at a catheterized urine flow rate of 12ml/sec 
d. Post void residual urine > 50ml 
Analysis 
All statistical analyses were performed using Statistical Package for the social 
Sciences (SPSS 11.0) for windows. Categorical data was presented using 
frequencies and percentage. Continuous data was described using mean ± 
standard deviation or median and range. Associations between categorical 
variables were assessed using chi-square test with yates’ correction or fisher’s 
exact test. Continuous variables were compared using student‘t’ tests and  
Mann-Whitney tests were used for non-normal data. A p-value less than 0.05 
was considered statistically significant.  
 
RESULTS 
Patients included in final analysis 
A total of 90 patients were recruited for the study. Of 90 patients, 65 (72.2%) 
were males and 25 (27.8%) were females.  
Prevalence of bladder dysfunction   
Of 90 patients, 45 had urodynamic study according to the inclusion criteria and 
45 others did not have urodynamic evaluation (non-urodynamics group). Over all 
37 patients (41.1%) had bladder dysfunction and 53 patients (58.9%) did not 
have bladder dysfunction. In the urodynamic group, 35 of 45 (77.8%) had bladder 
dysfunction as defined in the study. In the non-urodynamics group, only 2 of 45 
patients (4.4%) had bladder dysfunction. Age of the patients ranged from 20 to 
58 years (mean age ± SD - 45.6 ± 8.12 years).  Male patients were slightly older 
than females (46.23 ± 8.0 years in males against 44.2 ± 8.1 years in females). 
One half of the males and one fourth of the females had bladder dysfunction (P= 
0.012) (table 3).  
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Patients were categorized according to the age into three groups namely: 1) 18 
to 39 yrs (21.1%) 2) 40-50 yrs (48.9%) and 3) >50yrs (30%) (Figure 3). Bladder 
Figure 3: Prevalence 
of bladder dysfunction 
according to age 
group. 
dysfunction was seen more often in subjects with age >50 years (45.9%) (P = 
0.012). A few patients (7/90) were type 1 diabetics and majority (83/90) were 
type 2 diabetics. Bladder dysfunction was seen often in type 2 diabetics, however 
it was not statistically significant (P =0.610). Mean duration of diabetes was 6.7 
years (range 1-25). Bladder dysfunction was seen in subjects with longer 
duration of diabetes (6 years Vs 3 years) P= 0.042. 
Table 3: Comparison of demographic features in bladder dysfunction   
Bladder dysfunction Variable 
Yes No 
P value 
Age (years) † 49.0 ± 8.9  43.3 ± 8.6 0.001 ** 
Males§ 32 (49.2%)  33 (50.8%) 
Females§ 5 (20%) 20 (80%) 
0.012 * 
Type I Diabetes§  3 (42.9%) 4 (57.1%) 
Type II Diabetes§ 34 (41%) 49 (59%) 
0.610  
Duration of diabetes (years) ‡ 6 (1 -25) 3 (1 -25) 0.042*  
† - mean ± standard deviation 
‡ - median (range) 
§ - percentage 
* - significant    
** - Highly significant  
 
Bladder dysfunction was seen 10 (18.9%), 24(70.6%) and 3(100%) in those who 
have mild, moderate and severe LUTS by IPSS (P <0.001) as denoted in table 4. 
There was no correlation between IPSS and the severity of bladder dysfunction.  
Bladder dysfunction was seen more often in those who complained of LUTS 
during questioning (P= 0.05).  
 
 
Table 4: Comparison of Frequency –Volume chart (bladder diary), uroflowmetry 
& Bladder voiding efficiency in bladder dysfunction  
Bladder dysfunction Variable 
Yes No 
P value 
Mild 10 (18.9%) 43 (81.1%) 
Moderate 24 (70.6%) 10 (29.4%) 
IPSS § 
Severe 3 (100%) 0 
<0.001** 
Absence  12 (30%) 28(70%)  LUTS § 
Presence  25 (50%) 25(50%) 
0.05* 
Duration of LUTS (months)‡ 6 (0-24) 0 (0-36) 0.002 ** 
Day time frequency (times)‡ 7 (5-12) 6 (4-16) 0.264  
Night time frequency (times)‡ 2 (0-6) 1 (0-5)  0.007* 
24-hrs Fluid intake(ml) † 2750 ± 1151 2712 ± 964 0.870 
24-hrs urine volume (ml)† 2858 ± 1337 2386 ± 708 0.05* 
Maximum bladder volume(ml)  
(bladder diary) † 
582. 30 ± 218 502 ± 196 0.079 
<15ml/sec  35 (77.7%) 10 (22.2%) Qmax § 
>15ml/sec  2 (4.4%) 43 (95.6%) 
<0.001** 
 (>600ml)  19 (52.8%) 17 (47.2%) Voided volume  
During uroflow  §  (<600ml)  18 (33.3%) 36 (66.7%) 
0.05* 
>50ml 14 (70%) 6 (30%) Post void residue § 
<50ml 23 (32.9%) 47 (67.1%) 
0.003* 
Post void residue (ml) † 175.9 ± 232.4  52.4 ± 58.6 0.007* 
Bladder voiding efficiency (%) † 87.7 ± 17.3 94.56 ± 5.13 0.025* 
 
† - mean ± standard deviation  
‡ - median (range) 
§ - percentage 
* - significant   ** - Highly significant 
Bladder dysfunction was seen in those who had LUTS for 6 months or more 
(P=0.002). Bladder dysfunction was seen more often in those who had nocturnal 
frequency (P=0.007). Diabetics with bladder dysfunction has slightly increased 
intake of fluid, but the difference between the groups was not significant 
(P=0.870). However there was significant difference between the group with 
bladder dysfunction and the group that did not have dysfunction in 24-hr urine 
output. It could be attributed to hyperosmolar state in poorly controlled diabetes, 
as evident by the increase in mean HbA1C level (8.46±2.03%) in those with 
bladder dysfunction. However it was not statistically significant from HbA1C 
levels seen in group which did not have bladder dysfunction. The mean 24-hr 
urine output in subjects with bladder dysfunction was 2858 ± 13ml and it was 
2386 ± 70ml in those who did not have dysfunction(P=0.05). 
There was a significant difference between subjects with bladder dysfunction and  
Those who did not have bladder dysfunction, when their peak urine flow was less 
than 15ml/sec (P=<0.001), voided volume was more than 600ml (P= 0.05) and 
post void residue was more than 50ml (P= 0.003). When the post void residual 
urine values was individually computed for both groups, patients with bladder 
dysfunction had significantly different high mean volumes as compared to those 
who did not have bladder dysfunction (175.9 ±232.4ml Vs 52.4 ± 58.6ml)  (P 
=0.007). Mean bladder voiding efficiency was also significantly lesser in 
dysfunction group than in the group that did not have bladder dysfunction (87.7 ± 
17% Vs 94.56 ± 5.13%) (P=0.025). 
 
 
Prevalence of various urodynamic abnormalities in dysfunction group 
The prevalence of various urodynamic abnormalities in detrusor activity, first 
sensation, maximum cystometric capacity, bladder compliance, bladder outflow 
obstruction (Pdet at Qmax of ≥40cmH2O + catheterized urine flow rate of 
12ml/sec), hypocontractile detrusor (Pdet at Qmax <10cmH2O) and increased 
post void residue (>50ml) among those who had bladder dysfunction in the 
urodynamic group is shown in table 5. Increased maximum cystometric capacity 
was the commonest abnormality seen. 
 
Table 6. Prevalence of various urodynamic abnormalities 
Urodynamic abnormalities Prevalence – No (%) 
Detrusor overactivity 14 (31.1) 
Increased maximum cystometric 
capacity 
30 (66.6) 
Decreased bladder compliance 15 (33.3) 
Delayed first sensation  15 (33.3) 
Bladder outflow obstruction 15(33.3) 
Increased post void residue 25 (55.6)  
 
Comparison of urodynamic parameters in bladder dysfunction 
Delayed onset of first sensation of filling (>250ml or 50% of maximum 
cystometric capacity), increased maximum cystometric capacity (>600ml), peak 
catheterized flow rate (Qmax Uro), post void residual urine (>50ml) and abnormal 
detrusor contraction (Pdet Qmax < 10 or > 40 cmH2O) were significantly different 
between those who had bladder dysfunction and those who did not have 
dysfunction. However detrusor overactivity, compliance, detrusor pressure at 
peak catheterized flow rate (Pdet at Qmax Uro) was not significantly different 
between the two groups as denoted in table 7.  
Table 7– Significance of urodynamic parameters in bladder dysfunction  
 
† - mean ± standard deviation 
‡ - median (range) 
§ - percentage 
* - significant   ** - Highly significant 
 
Bladder dysfunction Variable 
Yes No 
P value 
>250ml  15 (100%) 0 First sensation 
§  <250ml  20 (66.7%) 10 (33.3%) 
0.009* 
>50 %  31 53 First sensation 
(of cystometric 
capacity) § 
<50%  6 0 
0.004* 
Detrusor overactivity 13 (92.9%) 1(7.1%) 0.102 
 (>600ml)  19 (52.8%) 17 (47.8%) Maximum 
cystometric 
capacity  § 
 (<600ml)  18 (33.3%) 36 (66.7%) 
0.05* 
>20cmH2O 14 (93.3%) 1 (6.7%) Compliance  § 
<20cmH2O 21 (70%) 9 (30%) 
0.077 
Qmax Uro (ml/sec) † 10.7 ± 4.3 14.4 ± 3.6 0.016 * 
Pdet at Qmax Uro(cm H2O) †  41.4 ± 21.5 32.4 ± 15.8 0.401  
Pdet Qmax < 10 or > 40 § 23 (88.5%) 3 (11.5%) 0.05* 
Post void residue (ml) † 175.9± 
232.49 
52.4 ± 58.6 0.007 * 
Comparison of clinical parameters in bladder dysfunction  
Among the clinical parameters studied, presence of peripheral neuropathy was 
the only parameter found to be significantly different between the bladder 
dysfunction group and the group that did not have bladder dysfunction (P=0.018) 
(table 8). Presence of retinopathy, nephropathy, blood pressure values, body 
mass index (BMI) and associated diseases were not significantly different 
between the two groups. When biothesiometry and monofilament assessment 
was correlated individually with presence or absence of bladder dysfunction, only 
abnormal monofilament values were significantly different between the bladder 
dysfunction and the group without bladder dysfunction (P=0.022).  
Table 8: Comparison of clinical parameters in bladder dysfunction  
Bladder dysfunction Variable 
Yes No 
P value 
BMI (kg/m²)† 24.6 ± 4.6 24.7 ± 4.3 0.160 
Systolic blood pressure (mmHg) † 128 ± 19.9 126.6± 11.6 0. 588 
Diastolic blood pressure (mmHg) † 80.16 ± 7.8 79.13 ± 6.4 0.535 
Biothesiometry (>20mv) § 13(54.2%) 11(45.8%) 0.129 
Monofilament (>4g) § 16(59.3%) 11(40.7%) 0.022* 
Peripheral neuropathy § 18 (58.1%) 13(41.9%) 0.018* 
Retinopathy § 15(50%) 15(50%) 0.226 
Nephropathy § 2 (50%) 2 (50%) 0.546 
Hypertension § 16(51.6%) 15(48.4%) 0.142 
Dyslipidemia § 8(30.8%) 18(69.2%) 0.204 
Ischemic heart disease § 5 (55.6%) 4(44.4) 0.281 
COPD § 2(66.7%) 1(33.3%) 0.367 
Hypothyroidism § 0 1(100%) 0.589 
† - mean ± standard deviation,  
§ - percentage, * - significant    
 
Comparison of biochemical parameters with bladder dysfunction 
Similarly there was no difference between the two groups in blood sugar levels, 
HbA1C, Microalbumin and lipid profile (table 9). Serum creatinine was the only 
biochemical parameter found to be significantly different between the bladder 
dysfunction group and the group which did not have bladder dysfunction.  Only 
two of the patients with bladder dysfunction had clinical renal failure.  
Table 9: Comparison of biochemical parameters with bladder dysfunction  
Bladder dysfunction Variable 
Yes No 
P value 
AC (mg %) † 140 ± 49 145 ± 45 0.678 
PC (mg %) † 224 ± 78 214 ± 76 0.620 
Serum creatinine (mg %) † 0.97 ± 0.24 0.86 ± 0.14 0.018* 
HbA1C (%) † 8.46 ± 2.03 8.43 ± 1.85 0.420 
Microalbumin (mg) † 69.05 ± 88.46 46.6 ± 79.15 0.312 
Cholesterol (mg%) † 178.14± 42.36  182.15± 44.37 0.914 
Triglycerides (mg%) † 162. 27 ± 69.34  153.45 ± 78.18 0.360 
HDL (mg%) † 34.6± 6.18 36.94 ± 6.5 0.611 
LDL (mg%) † 114.05 ± 32.83 120.06 ± 37.27 0.509 
 
† - mean ± standard deviation 
* - significant    
 
 
 
 
 
 
DISCUSSION 
In the previous studies, according to the diagnostic methods, criteria and patient 
characteristics, the frequency of diabetic cystopathy varies from 26% to 87% [6, 7, 
9, 79]. The varied frequency of diabetic bladder dysfunction reported in the 
literature is due to varied definitions adopted and different combinations of 
investigations used by the authors. Frimodt-Moller et al first reported detailed 
clinical characteristics of bladder dysfunction in unselected diabetic patients. 
They characterized diabetic cystopathy as loss of sensation detected by elevated 
electrical bladder perception threshold which was found in 38% of patients [80]. 
According to the criteria proposed by Kahan et al [77], which defined diabetic 
cystopathy as an increase in bladder capacity to more than 400ml with flat trace 
on cystometry, 36% of diabetic subjects had diabetic cystopathy. Ueda et al [39] 
reported that 32% of diabetic patients had diabetic cystopathy using the criterion 
that bladder capacity exceeding 500ml was abnormal. In our study, with criteria 
for overt diabetic cystopathy which included maximum cystometric capacity 
(>600ml), Pdet at Qmax <10cmH2O at catheterized flow rate of less than 
12ml/sec and impaired first sensation (>250ml or 50% of cystometric capacity) 
and PVR ≥50ml, overt diabetic cystopathy was found in 7/45 (15.5%) patients. 
When all the criteria for bladder dysfunction were applied, Overall prevalence of it 
was noted in 41.1% of the patients. 
Kebapci et all has shown that IPSS was not different between those who have 
bladder dysfunction and those who did not have bladder dysfunction in their 
study of 54 type 2 diabetic patients. It was also not different among those who 
had diabetic cystopathy and those who had other bladder dysfunction [82]. In our 
study mean IPSS was significantly different among the bladder dysfunction (9.7 ± 
6) and non dysfunction group (4.3 ± 3.3) (P<0.001). However we could not 
establish a correlation between the IPSS and severity of bladder dysfunction. 
There was highly significant difference in peakflow among the bladder 
dysfunction group (17.13ml/sec) and group without bladder dysfunction (25.02 ± 
8.32ml/sec) (P<0.001). The same difference noted for post void residue>50ml 
between these groups (70% Vs 50%) (P= 0.003). Thus its should be possible to 
predict the chances of bladder dysfunction in diabetics with basic tools of 
evaluation of lower urinary tract like uroflowmetry, estimation of post void residue 
and IPSS (peak flow less than 17ml/sec, IPSS >10 and PVR >50ml). However 
the sample size should be larger, to get more significant and consistent 
prediction of bladder dysfunction.   
A number of clinical studies have reported detrusor overactivity as the most 
frequent finding, ranging from 39% to 61% of diabetic patients [88]. Detrusor 
overactivity can be due to bladder outflow obstruction or neurologic disease and 
moreover, it is common among elderly incontinent subjects [39]. Incontinence  
due to detrusor overactivity among women in the general population increases 
with age, starting at a prevalence / incidence of 20–30% in young-adult life (<40 
years), rising to 30–40% in middle age (40–60 years), and 30–50% in the elderly 
(>60 years) [88, 89]. Similarly detrusor overactivity is also of high prevalence 
among elderly men with prostatic enlargement [90]. Men with diabetes have an 
increased risk of developing LUTS, reported to be 25–100% higher than in the 
general male population [91]. In our study, in the absence of neurological disease 
other than diabetic neuropathy, among patients of bladder dysfunction, detrusor 
overactivity was seen in 13 patients (females -4, males -9) with prevalence of 
29%. Of them, isolated detrusor overactivity, detrusor overactivity associated with 
BOO and associated with cystopathy was seen in 38.5%, 38.5% and 23% of 
patients respectively.  Among females with detrusor overactivity, it was seen as 
an isolated abnormality in two and was associated with cystopathy in others. 
Among males with detrusor overactivity, it was seen isolated in 3, associated with 
BOO in 5 and associated with cystopathy in one.  Mean age of males with 
detrusor overactivity was 51.4 years. Mean age of females with detrusor 
overactivity was 47.7 years.  
Within the male population the most important differential diagnosis, and the one 
that frequently coexists with diabetic cystopathy is BOO [92]. Kaplan et al found 
that bladder outflow obstruction was seen in 66 men (prevalence of 36%) among 
their 182 patients who were evaluated with urodynamics [35]. 
Bladder outflow obstruction was seen 15 (33.3%) patients in our study. All except 
one were men. A 55 years old postmenopausal lady had BOO. The mean age of 
all men was them 47.2 years (range 39 – 58 years). 3 patients with BOO also 
had features of diabetic cystopathy. 5 had associated detrusor overactivity.  
The patients who had bladder dysfunction had significant difference in maximum 
bladder volume as recorded in the bladder diary and higher 24-hr urinary volume 
(urine output). This could also be useful to predict bladder dysfunction provided 
the hyperosmolar state due to poorly controlled diabetes is ruled out. In our study 
both the bladder dysfunction and non-dysfunction groups had raised HbA1C 
levels indicating inadequate glycemic control. This could be the reason for larger 
urinary volumes seen among subjects with bladder dysfunction. Kepabci et al 
have shown in their study that higher HbA1C levels were associated with higher 
prevalence of bladder dysfunction even though it was not statistically significant. 
There is well established correlation between bladder dysfunction and diabetic 
neuropathy [93]. The presence of abnormalities on neurological examination has 
been shown to predict bladder dysfunction. More than 85% of patients with 
positive sacral cord signs had abnormalities of detrusor contractions in one study 
[35]. In another study on 29 diabetic patients, 38 of whom had voiding dysfunction 
as defined by the presence of an abnormality in either flow rate, flow pattern, or 
post void residue, voiding dysfunction was strongly correlated with presence of 
neuropathy (P<0.001) [41]. Overall, a correlation ranging from 75% to 100% have 
been reported in previous studies [76]. In our study, 18 of the 31 (58.1%) patients 
with clinical evidence of peripheral neuropathy in lower limbs had bladder 
dysfunction, whereas only 19 of the 59 patients without neuropathy had bladder 
dysfunction (P=0.018). Presence of overt peripheral neuropathy could be used to 
predict the bladder dysfunction.  
Esteghamati et al showed an inverse correlation between retinopathy and 
detrusor instability in an urodynamic study done in asymptomatic diabetic 
subjects [86]. About half the patients with diabetic cystopathy showed signs of 
retinopathy in study of 124 diabetic subjects [80]. In our study, prevalence of 
retinopathy was 33%.There was no significant difference between bladder 
dysfunction group and group which did not have bladder dysfunction (P=0.226). 
Bladder dysfunction was seen 22 patients without retinopathy.  
In a small study on 17 insulin dependent diabetic patients with median age of 45 
years (27-67years) and mean diabetes duration of 23 years (14-44years) who 
suffered from diabetic nephropathy, no association was found between diabetic 
cystopathy and progression of nephropathy [10]. The frequency of nephropathy 
was 19% among patients with diabetic cystopathy in the study by Frimodt-Moller 
[80]. Serum creatinine was highly significant among those with nephropathy and 
cystopathy (P<0.001). In our study serum creatinine was significantly different in 
bladder dysfunction group and those who did not have bladder dysfunction. 
However there was no significant correlation between bladder dysfunction and 
nephropathy. There were two patients with renal failure in the bladder 
dysfunction group, whose altered renal function is probably because of diabetic 
nephropathy rather than cystopathy as both had macroalbuminuria.  
As denoted by Kaplan et al [35], classical diabetic cystopathy was not the common 
abnormality seen among diabetic subjects; we found a variety of urodynamic 
abnormalities as denoted in the table 6. The present study was one to evaluate 
the prevalence of bladder dysfunction of probably asymptomatic diabetic subjects 
who had never come to urology department owing to their lower urinary tract 
symptoms and were recruited from a diabetic clinic of an endocrinology 
department.  
Although most of the patients in our study were urologically asymptomatic or had 
mild symptoms as evidenced by the low mean IPSS, majority (35/45) of those 
who had urodynamic evaluation had atleast one urodynamic abnormality. 7 
(15.5%) had overt diabetic cystopathy and they never bothered to the extent of 
seeking urological advise. It indicates the very innocuous and occult nature of 
development of bladder dysfunction in diabetics. Unless they were questioned 
appropriately and diagnosed, they would have developed the classical 
cystopathy and its complications.  
It’s also worrisome to anticipate such complications happening in the group who 
did not have urodynamic evaluation. However considering ethical reasons, 
invasive urodynamic evaluation was not done in them.  If we are able to predict 
the bladder dysfunction consistently using the uroflowmetry, post void residue 
and IPSS, it can be applied for screening the asymptomatic subjects.  If any 
abnormality is detected during initial screening, they can be subjected to further 
urodynamic study, which is a more sensitive and accurate method of evaluating 
voiding function. The findings in this study suggest the development of diabetic 
bladder dysfunction begins far before symptoms appear or when symptoms are 
mild in nature. It highlights the importance of early screening for bladder 
dysfunction, especially for those who are at risk.  
 
 
 
 
 
 
CONCLUSIONS 
 
From this study, it can be concluded that  
1) The prevalence of bladder dysfunction in diabetic subjects between 18 to 
60 years of age from Tamilnadu attending a diabetic clinic was 41.1%.  
2) Abnormal urodynamic findings other than diabetic cystopathy are 
commonly seen among the diabetic subjects. 
3) IPSS, Uroflowmetry and estimation of post void residual urine might be 
useful to screen the diabetic subjects before urodynamic evaluation to 
diagnose and characterize bladder dysfunction.  
4) Bladder dysfunction is seen often (35/45) in patients with moderate LUTS 
than in asymptomatic patients (2/45) or those with mild LUTS. 
5) Bladder dysfunction is significantly associated with peripheral neuropathy 
and association with other microvascular complications like retinopathy 
and nephropathy is not significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
LIMITATIONS 
1) Small sample size of one particular community (Tamil speaking local 
people) may not represent the whole of the population of diabetic subjects 
in the country. Regional difference among various subjects and its 
implication on bladder dysfunction is not addressed. Larger sample size 
involving participation of subjects from varied geographical distribution 
might be useful to overcome the regional bias.  
2) To elucidate the prediction of the chance of developing bladder 
dysfunction by the parameters studied may give erroneous value, 
particularly in the small present population of diabetic subjects.  
3) We have only evaluated for peripheral somatic neuropathy (in the 
extremities) and the presence of autonomic neuropathy was not 
evaluated.  
4) Some of the abnormal findings may normally occur with aging. However, 
because of ethical issues in performing invasive urodynamic studies on 
asymptomatic or mildly symptomatic patients, there was no real 
representation of bladder findings from the asymptomatic group even 
though calculation of bladder voiding efficiency was used to predict 
voiding dysfunction in them. Urodynamic evaluation in these subjects can 
throw light on the true prevalence of asymptomatic bladder dysfunction 
and can be detected at a very early stage.    
5) The lack of associations between some of the parameters evaluated in 
this study might be due to the relatively small sample size and the 
consequent low power of the study. Studies with larger sample sizes can 
be performed in future to more accurately predict the bladder dysfunction. 
It should be possible to exactly predict the chances of bladder dysfunction 
using mathematical models with application of simple and clinically 
applicable measurements like uroflowmetry, post void residue and IPSS.   
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ANNEXURE  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proforma 
 
Name:                                          Age/Sex: 
 
Hospital No:                                Address for communication: 
 
Associated diseases:  
 
Date of diagnosis of diabetes:   
History:   
1) Duration of Diabetes: 
2) Lower urinary tract symptoms (LUTS): 
3) Duration of LUTS:   
4) Other urological symptoms 
a) Hematuria, Calculuria, Chyluria, Necroturia   yes / no 
b) UTI / Instrumentation:       yes / no 
c) Previous voiding dysfunction:     yes / no 
5) Neurological, cardiovascular and peripheral vascular diseases. 
6) Angina / Claudication / TIA:       yes / no 
 
 
Tools for evaluation:   
1) International Prostate symptoms score:  
2) Bladder diary for 24 hours:  
3) Uroflowmetry and post void residual urine:  
Examination:   
Height:                          Weight:                                 BMI: 
Pulse:                             BP: 
Distal pulses/ Reflexes:    
 Upperlimb: 
 Lower limb:                              
Peripheral sensation:  Vibration / Pinprick    
Biothesiometer: 
Monofilament: 
Fundoscopy:  
Dry skin/ Hair loss / Deformities: 
P/A: Bladder distension and other masses. 
DRE: Sphincter tone, BCR, Prostate size. 
External Genitalia:                                      
Perineal sensation:  
Spine:                                          
Investigations:    
1) Serum creatinine        2) AC/PC    
3) HbA1C            4) Lipid profile 
5) Micro albumin/mg/g of creatinine or 24 hr protein.   6) Urine Microscopy   
7) Urine culture and sensitivity 
8) X-ray KUB and Ultrasonography (when clinically indicated) 
9) Urodynamic Parameters when applicable 
Diagnosis: 
Consent:  
I, Mr / Mrs / Miss……………………., have been recruited to be a participant of 
this study. I was explained by the doctor undersigned that this study is intended 
to know occult bladder dysfunction in diabetic patients like me. I know that this 
condition doesn’t manifest early and when if manifests, it is usually associated 
with multiple complications. I know that this study involves invasive procedures 
like urethral and rectal catheterization followed by urodynamic evaluation. I was 
informed of the possible complications involved in this study. I am aware that the 
results of this study may or may not have bearing on my treatment. I give 
consent for the proposed study after knowing all the benefits and complications. 
 
Dr.R.Shanmugasundaram     …………………………. 
         
Date        Name of the patient 
Name Age Sex H.No.  TOD DOD IPSS UF VV PVR Ht.  Wt. PR BP BMI M
Kamala 57 f 038203b 2 14 12 33 610 23 146 56 80 140/80 26.3 4g
Varalakshmi 51 f 907904c 2 1½ 9 30 541 176 155 63 80 120/80 26.2 >1
Gracy Albert 40 f 100605D 2 8 9 36 502 69 160 58 84 130/80 22.7 2g
Sundaram 43 m 102734d 2 1 9 23 934 20 157 46 84 120/80 18.7 2g
T.S.Saroja 55 f 947944b 2 20 10 16 489 5 159 78 78 140/70 30.9 2g
Lakshmi 54 f 057182d 2 1 9 36 267 10 156 87 72 150/90 38.7 2g
chandran 55 m 368956a 2 7 9 9 210 10 167 75 76 110/70 26.9 2g
Annamalai 46 m 825817b 2 1 9 15 315 5 164 57 68 140/80 21.2 2g
Vincent 37 m 071003c 1 6 0 9 580 130 174 55 78 110/70 17.5 2g
Gangadharan 43 m 248163c 1 5 16 10 205 10 157 55 80 100/90 22 6g
Manoharan 45 m 701260a 1 25 1 30 670 63 164 72 86 130/90 26.8 4g
Natarajan 51 m 991144c 2 6 21 12 603 21 184 75 82 130/80 22.2 2g
Balaraman 50 m 823096c 2 1 0 9 352 191 167 53 76 130/90 19 10
Jeyaprakash 54 m 229293c 2 1 9 14 465 47 168 59 82 110/70 20.9 2g
Parasuraman 51 m 928071c 2 1½ 9 22 600 13 165 65 72 120/80 23 10
Gnanasekar 39 m 338946c 2 6 15 15 347 75 168 71 76 120/80 24 2g
Vijayakumar 57 m 756053c 2 13 23 9 159 210 165 69 78 160/80 25.3 4g
Naushadh 46 m 112049D 2 1 9 12 169 19 167 71 60 126/70 25.5 2g
P.R.Harinath 20 m 085619c 1 7 12 25 447 7 157 45 110 130/80 18.3 2g
Kesavan 53 m 955002b 2 12 12 21.5 260 61 180 90 76 120/80 27.8 6g
Balu 52 m 919615c 2 3 11 24 232 5 170 55 86 80/60 19 6g
Mohanraj.T.E 55 M 110355D 2 7 9 20 252 7 158 80 82 170/100 32 2g
Rani 44 f 444743c 2 4 9 14 164 26 159 60 68 138/84 23.7 2g
Naushadh 46 m 112049d 2 1 9 12 269 19 167 71 60 126/70 25.5 2g
Subramaniam 58 m 081887D 2 10 8 12 264 10 164 86 84 140/80 31.8 4g
Susai 50 m 818668c 2 3 4 15 475 210 168 57 90 110/70 20.2 10
Janakiraman 57 m 253960a 2 18 28 6 341 75 160 62 80 140/90 24.2 4g
Madhavi 43 f 700631a 2 9 10 36 466 45 153 72 72 110/70 30.8 2g
Jeganathan.S 48 m 320660c 2 6 11 7.3 247 5 170 70 76 150/80 24.2 4g
Syed Moosa 50 m 492867a 2 22 7 9 24 210 162 67 76 140/80 25.5 10
Antony Raj 51 m 259866c 2 11 12 26 384 88 164 66 82 120/80 24.5 4g
Sumathy 34 f 640171c 2 2 12 38 524 22 151 51 64 120/80 22.4 2g
Ilakkuvan 56 m 155088d 2 10 13 8 353 7 158 55 80 130/80 23.2 2g
Mahendiran 44 m 272348B 2 10 14 12 202 37 177 95 76 110/70 30.3 2g
Banumathi.S 50 f 833204c 2 2 8 21 296 10 160 59 70 130/80 23 2g
Anusuiya.S 47 f 802119c 2 11 9 24.2 620 36 158 68 88 180/90 27.2 >1
Somasundaram 50 m 106743d 2 3 7 8 505 60 155 54 86 110/70 22.4 >1
Rajenderan. P 53 m 146250d 2 10 9 10 300 10 163 60 80 130/80 22.6 2g
Ramalingam 49 m 080338d 2 15 11 15 524 9 162 56 72 120/80 21.3 2g
sundaramurthy 56 m 243325c 2 15 3 10.8 238 26 157 48 76 140/80 19.5 2g
Rajagopal.K 38 m 464150c 2 2 4 12 263 7 151 58 85 120/80 25 2g
Puniyakodi 39 m 983115c 2 9 m 8 32 294 5 167 74 55 130/80 26.5 2g
Nasuruddin 52 m 278183b 2 12 11 13 522 9 172 62 72 110/70 21 4g
Neelavathi 46 f 109842a 2 3 15 24 338 42 156 83 84 120/80 34.1 2g
Seethamma 36 f 190987c 2 1 9 49 628 36 151 70 70 130/80 30.7 6g
Vijayan 29 m 284941c 1 4 3 19 432 14 163 49 88 120/70 18.6 2g
Lakshmi 24 f 882372c 1 11 4 33 858 5 151 45 72 110/70 19.7 2g
puroshothaman 44 m 441505c 2 5 2 18 726 48 167 73 76 110/70 26.2 2g
Deivayanai 34 f 812741c 2 2 1 29 202 5 145 57 78 110/70 27.1 2g
Krishnamoorthy 50 m 030608b 2 9 2 28 957 25 162 71 80 140/90 27.1 2g
Rose mary 50 f 966064c 2 3 3 30 301 15 152 45 80 140/80 19 2g
Banumathi 47 f 099419d 2 2 4 30 386 15 149 71 80 120/80 32 2g
Lakshmi 44 f 003651a 2 1 2 20 270 5 158 63 84 120/70 25.2 6g
John Abraham 40 m 421149a 2 5 3 25 610 14 165 63 72 120/80 23.1 2g
Vijayakumar.S.K 43 m 045174d 2 6 4 15 214 10 164 67 90 140/90 24.3 4g
Rani 47 f 084177d 2 8 2 26 538 20 154 71 76 110/80 29 2g
Haridoss 49 m 999333c 2 6 m 0 25 412 25 160 72 80 130/80 28.1 2g
Palani.A.D 37 M 122855C 2 2 2 24 175 8 170 69 76 120/80 23.9 2g
Raghunathan 46 m 061986d 2 1 2 20 371 10 168 69 80 130/80 24.4 2g
Gnanasekaran 53 m 076404d 2 10 4 16 393 4 185 81 80 120/80 23.7 2g
Shanmugam.S 31 m 021932d 2 6 m 2 32 228 5 165 59 78 120/80 21.5 2g
Pappa 49 f 071788d 2 15 3 18 175 5 157 53 90 130/80 21 12
Annakili 39 f 097847d 2 2 6 44 489 25 159 70 88 140/80 27.7 2g
Suresh Babu 47 m 546892b 2 6 2 20 842 123 161 61 88 150/90 23.5 2g
Radhakrishnan.S.V 55 M 767973C 2 20 5 20 309 8 160 68 82 130/90 26.6 2g
Sumathi Rani 36 f 287033c 2 2 0 29 784 49 168 91 84 140/80 32.2 2g
Vinod Chander 32 m 846405c 2 2 2 15 251 5 167 80 96 100/60 28.7 4g
Sundaram 51 m 303287b 2 2 7 19 623 58 170 74 84 120/80 25.6 2g
R.K.Venkatesan 34 m 626174c 2 1 7 18 154 10 172 78 82 132/80 25 2g
Parimala 48 f 027551d 2 10 4 19 331 14 146 45 72 110/70 21.1 2g
Anandan.S 42 m 759110c 2 2 2 39 696 51 177 82 76 120/80 26.2 2g
Lakshmi 52 f 637313 2 7 2 47 512 5 151 71 80 140/80 31.1 4g
Krishnaswamy.R 40 m 637641c 2 1 5 20.7 293 5 168 70 86 140/90 24.8 2g
Elumalai 33 m 132488c 2 1 0 20 311 99 169 66 84 130/80 23 2g
Sakthivel 55 m 449877 2 25 1 19 350 5 170 65 80 120/80 22.5 2g
Geetha.S 47 f 127656d 2 12 6 24 360 5 160 55 86 130/80 21.5 2g
Govindaraj.M 54 m 070583d 2 10 7 23 512 93 166 49 78 126/80 17.8 10
Chandru 42 m 650044c 2 4 2 20.6 745 52 162 57 84 120/70 21.7 4g
Annadurai  46 m 941395c 2 6 1 23 129 4 161 62 78 140/80 23.9 4g
Ishaar shariff 43 m 895984c 2 6m 1 20 207 5 169 113 88 150/90 39.6 2g
Mohan.N.K 50 m 300227b 2 5 3 21 172 10 167 70 76 120/80 25.1 2g
Subramani 53 m 074069d 2 1 6 31 416 19 165 50 80 130/80 17.9 2g
Suresh kumar 40 m 478600 1 7 4 25 458 19 158 45 68 110/80 18 2g
Baskar.S 42 m 978786c 2 8 6 36 534 38 170 67 80 114/80 23.2 2g
Srinivasan G 41 m 754208b 2 8 3 25 533 114 174 80 72 140/80 26.4 2g
Esther Shanthi 29 f 138495d 2 1½y 3 34 288 24 155 69 70 130/90 28.7 2g
Sivakumar 50 m 438547a 2 15 0 31 545 37 175 75 88 110/80 24.5 2g
M.R.Sriram 32 m 941508c 2 1½y 3 27 384 5 176 93 80 140/90 30 2g
Arockiaswamy.B 57 m 437689c 2 3 1 18 213 10 175 53 64 110/80 18.3 2g
Shanmugam.K 50 m 587254c 2 2½y 1 18 168 10 156 56 84 130/80 23 2g
 
 
 
 
 
 
 
 
 
 
 
 
 S. 
Cr.  AC PC HbA1C 
 
Microalb Chol.  TG HDL LDL Ass. diseases FS MCC Comp. DI IC
0.8 255 178 10.8 70 108 93 29 57
HT, hypothyroidism, 
depression 201 759 16 Nil 
SI
51
0.6 155 196 8.6 488 249 262 46 151 Hypertension,Dyslipdemia 135 648 16 nil nil
0.7 173 267 9.6 22 197 238 38 118 Dyslipidemia 152 764 9 Prt UI
0.9 97 234 7.9 24 210 192 35 128  277 699 6 Nil Ni
0.8 202 299 9.4 52 182 166 37 123 hypertension, IHD 162 674 10 Nil Ni
1 144 235 8.2 42 162 95 32 120 hypertension 206 576 32 Prt Ni
1.1 129 179 6.3 10 140 165 43 68 IHD 357 590 9 Nil Ni
1 98 146 6 44 235 207 35 157  174 594 39 Nil Ni
0.9 218 167 6.8 5 173 37 46 118  271 591 24 Nil Ni
0.9 101 159 6.8 60 143 152 29 85 Asthma 337 522 20 Nil Ni
1 111 100 6.6 22 126 82 41 73
athsma, PSVT, 
Hypertension, 
Dyslipidemia 337 717 11 Nil Ni
0.8 171 276 8.9 8 235 200 44 136  179 805 4 Nil Ni
1 93 138 5.7 27 140 254 29 78  327 717 38 Nil Ni
0.8 143 173 10.6 63 138 72 29 102
chronic liver disease, 
Portal HTN,  312 618 27 Nil Ni
0.9 106 247 7.1 33 97 225 28 45 Hypertension, IHD 219 726 12 Nil Ni
1 150 219 8.4 22 144 233 28 78 hypertension 225 692 12 Nil Ni
2.2 110 324 8.6 342 232 213 36 154 hypertension, IHD 321 670 20 Prt Ni
1 158 238 8.6 150 192 208 40 117  205 438 10 Nil Ni
0.8 134 288 12.5 150 154 82 37 104  155 695 12 Nil Ni
0.8 186 322 10.9 220 178 126 38 112  336 887 8 Nil Ni
1 212 287 13 38 228 187 36 150 cardiomyopathy 278 611 24 Prt Ni
0.9 161 248 10.3 150 226 178 32 126 hypertension 188 520 7 Prt UI
0.7 150 261 8.1 12 170 120 32 123 Asthma 178 461 15 nil Ni
1 158 238 8.6 >150 192 208 40 117  205 438 10 nil Ni
 
 
0.9 118 183 6.4 58 146 133 28 101 hypertension 307 664 16 nil Nil 
0.8 84 151 7.6 9 163 124 31 113  244 656 10 Prt Nil 
1 122 152 6.2 6 262 378 42 144 duodenal ulcer 169 299 19 Nil Nil 
0.9 105 151 7.2 <5 149 85 38 95 hypertension 178 610 24 Nil Nil 
1 124 293 8.6 24 149 98 28 95
post mitral valve 
repalcement 211 483 24 Prt Nil 
1.3 108 168 10.5 113 269 108 50 202
ESRD- status post renal 
Tx 659 ### 20 Nil Nil 
1.1 61 148 7.4 104 150 173 36 80
Hypertesnion, 
dyslipidemia, IHD- 
POST CABG 178 428 7 Prt Nil 
0.6 121 158 9.7 23 235 91 45 171  201 689 11 Nil Nil 
1 220 417 10.9 <5 198 124 33 144 hyperstension 118 355 20 Prt Nil 
0.9 112 138 6.6 <5 128 85 29 85 Panic disorder, IHD 134 271 16 Prt UI 
0.7 115 150 7.6 20 173 191 36 103  214 648 10 Prt Nil 
0.9 136 312 12.8 332 180 153 33 116
hypertension, diabetic 
foot 309 704 11
Prt
Nil 
1.2 69 210 10 6 134 91 32 77
Hypertension, 
dyslipidemia, IHD 184 311 24
Prt
UI 
1 312 411 9.3 23 176 136 30 110  209 519 24 Prt UI 
0.8 122 283 9.2 56 262 256 50 174
hypertension, IHD, 
Effort angina, pul.TB 65 637 10 nil Nil 
1.1 136 132 6.1 199 177 116 31 132 dyslipidemia 90 654 14 nil Nil 
1 129 278 9 <5 135 305 31 67 dyslipidemia 278 832 18 nil Nil 
0.9 140 200 6.5 24 172 114 32 113 cardiac arrhythmias 150 677 24 nil Nil 
0.9 166 257 12.4 63 159 181 27 99
hypertension, IHD, LV 
dysfucntion 258 606 18 nil Nil 
0.7 166 272 9.5 235 190 146 36 138 Hypertension 241 908 18 nil Nil 
0.7 119 98 6.2 64 126 105 28 84 Hypertension 235 782 9 nil Nil 
0.8 162 190 8.8 20 167 60 51 98 nil      
0.5 233 174 8.7 22 141 79 32 54       
0.9 170 218 7.9 <5 113 56 34 92 nil      
0.7 96 108 6.1 <5 162 159 31 99 nil      
1 149 203 7.4 26 181 164 32 142 Hypertension, dyslipidemia 
0.7 171 264 7.3 149 255 240 42 186 Dyslipidemia    
0.9 119 225 9.8 30 210 170 41 151 Hypertension, post menopausal 
0.8 88 130 5.7 <5 136 59 35 79 Dyslipidemia    
1.1 129 128 6.8 <5 153 100 39 88       
0.8 252 342 8.9 51 242 229 37 173 Dyslipidemia    
0.8 125 184 9.6 7 203 267 43 130       
1.2 137 274 6.1 >150 177 372 39 96 AK amputee, dyslipidemia 
1 93 120 6.3 15 165 84 29 121       
1 240 322 9.6 12 198 244 35 122       
1 170 267 10.8 29 152 93 31 110 hypertension, IHD-MI,dyslipidemia 
0.9 142 173 8.7 <5 153 92 31 84       
0.8 167 334 12.3 13 313 383 48 216 hypertension, dyslipidemia 
0.8 130 220 6.7 33 273 196 54 175 hypertension,dyslipidemia 
0.9 158 147 7.5 99 184 116 38 136       
0.9 118 177 7.6 24 220 187 38 153 dyslipidemia    
0.7 153 167 8.5 <5 162 125 41 104 hypertension, obesity  
1.2 147 252 8.8 <5 159 136 29 98       
0.9 83 104 6.6 15 154 60 44 90 post pneumonectomy-TB  
1 182 244 7.5 150 192 175 44 113 hypertension, dyslipidemia 
0.8 153 247 7.5 162 178 201 40 110 IHD, dyslipidemia   
0.9 103 128 5.7 <5 171 145 30 123 hypertension, dyslipidemia 
0.6 110 168 7.8 24 201 182 41 144 Dylipidemia, obesity  
1.1 106 215 6.4 7 212 152 42 151       
0.8 125 189 6.8 <5 218 286 40 121       
0.8 129 242 10 <5 131 79 25 88 IHD, dyslipidemia   
0.7 172 305 10.1 5 296 108 43 235 Dyslipidemia    
0.8 102 228 >13 48 119 79 29 57 Hypertension, pulmonary TB 
0.8 168 281 11.5 <5 210 138 40 150       
1 93 119 6.2 9 157 187 35 99 hypertension, dyslipidemia 
0.9 114 119 9.1 20 174 161 39 112 hypertension,metabolic syndrome 
1 112 78 6.4 5 183 85 29 163       
0.9 101 225 6.2 38 171 132 36 122 dyslipidemia    
1 144 295 12.2 16 162 87 30 109 Hypothyroidism   
1 135 210 8.2 15 162 129 33 84       
1 107 140 6.5 <5 153 87 31 104 hypertension    
0.9 148 351 8.5 14 166 203 40 104       
0.8 93 141 7.3 150 127 66 24 93 hypertension,IHD,dyslipidemia, bell's palsy 
0.9 226 350 10.1 3 186 165 31 139 infertility,dyslipidemia  
0.9 277 434 10.9 9 247 299 44 160       
0.9 177 270 7.8  172 132 35 122       
 
 
